The patents cover design and methods for creating integrated fluidic microchip devices. Microchip Biotechnologies (MBI) will use the technology licensed from GE Healthcare to develop and commercialize easy to use Sample-To-Answer systems using advanced microfluidic technologies. Microfluidics deals with the behavior, precise control, and manipulation of microliter and nanoliter volumes of fluids to perform life science assays.
Stevan Jovanovich, president and CEO of MBI, said: “Licensing these fundamental patents continues to build our strong intellectual property position in microfluidic devices. Microfluidic devices will play a critical role in next-generation instrumentation that delivers fully-automated, cost-effective bioassay solutions in the life sciences, applied sciences, and molecular diagnostics.”